B
Briana Foley
Researcher at Durham University
Publications - 9
Citations - 402
Briana Foley is an academic researcher from Durham University. The author has contributed to research in topics: Small molecule & In vivo. The author has an hindex of 6, co-authored 8 publications receiving 370 citations.
Papers
More filters
Journal ArticleDOI
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.
Kenneth He Huang,James Marvin Veal,Patrick Fadden,John W. Rice,Jeron Eaves,Jon-Paul Strachan,Amy F. Barabasz,Briana Foley,Barta Thomas E,Wei Ma,Melanie Silinski,Mei Hu,Jeffrey M. Partridge,Anisa Scott,Laura G. Dubois,Tiffany Freed,Paul M. Steed,Andy J. Ommen,Emilie D. Smith,Philip F. Hughes,Angela R. Woodward,Hanson Gunnar J,W. Stephen Mccall,Christopher John Markworth,Lindsay Hinkley,Matthew Jenks,Geng Lifeng,Meredith Lewis,James C. Otto,Bert Pronk,Katleen Verleysen,Steven E. Hall +31 more
TL;DR: A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compound library, and optimized analogues exhibited nanomolar antiproliferative activity across multiple cancer cell lines.
Journal ArticleDOI
Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90.
Patrick Fadden,Kenneth He Huang,James Marvin Veal,Paul M. Steed,Amy F. Barabasz,Briana Foley,Mei Hu,Jeffrey M. Partridge,John W. Rice,Anisa Scott,Laura G. Dubois,Tiffany Freed,Melanie Silinski,Barta Thomas E,Philip F. Hughes,Andy J. Ommen,Wei Ma,Emilie D. Smith,Angela Woodward Spangenberg,Jeron Eaves,Hanson Gunnar J,Lindsay Hinkley,Matthew Jenks,Meredith Lewis,James C. Otto,Gijsbertus J. Pronk,Katleen Verleysen,Timothy A.J. Haystead,Steven E. Hall +28 more
TL;DR: The chemoproteomics-based approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clinical studies.
Journal ArticleDOI
Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
Barta Thomas E,James Marvin Veal,John W. Rice,Jeffrey M. Partridge,Patrick Fadden,Wei Ma,Matthew Jenks,Geng Lifeng,Hanson Gunnar J,Kenneth He Huang,Amy F. Barabasz,Briana Foley,James C. Otto,Steven E. Hall +13 more
TL;DR: X-ray data show that the scaffold binds competitively at the ATP site on Hsp90, and cellular proliferation and client assays demonstrate that members of the series are able to inhibit HSp90 at nanomolar concentrations.
Journal ArticleDOI
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
John W. Rice,James Marvin Veal,Amy F. Barabasz,Briana Foley,Patrick Fadden,Anisa Scott,Ken Huang,Paul M. Steed,Steven E. Hall +8 more
TL;DR: The advanced evaluation of SNX-5422 as a treatment for non-small cell lung cancer (NSCLC), especially in cases where the cancer is driven by c-Met amplification or mutated EGFR forms that are resistant to EGFR inhibitors, is supported.
Journal ArticleDOI
The use of high-content screening for the discovery and characterization of compounds that modulate mitotic index and cell cycle progression by differing mechanisms of action.
TL;DR: An approach for characterizing inhibitors of Aurora kinase family members using high-content screening is validated by determining compound effects on the levels of the mitotic marker phospho-histone H3 (Ser10), indicating a block of cell cycle progression at M-phase.